DESIPRAMINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for desipramine hydrochloride and what is the scope of patent protection?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Alembic, Amneal Pharms Co, Ani Pharms, Chartwell Rx, Heritage, Novast Labs, Usl Pharma, and Validus Pharms, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for desipramine hydrochloride. Nine suppliers are listed for this compound.

Summary for DESIPRAMINE HYDROCHLORIDE

US Patents:	0
Tradenames:	3
Applicants:	10
NDAs:	18
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	61
Patent Applications:	2,698
What excipients (inactive ingredients) are in DESIPRAMINE HYDROCHLORIDE?	DESIPRAMINE HYDROCHLORIDE excipients list
DailyMed Link:	DESIPRAMINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for DESIPRAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital Plymouth NHS Trust	Phase 3
King's College London	Phase 3
NHS Lothian	Phase 3

See all DESIPRAMINE HYDROCHLORIDE clinical trials

Pharmacology for DESIPRAMINE HYDROCHLORIDE

Drug Class

Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for DESIPRAMINE HYDROCHLORIDE

Adrenergic Uptake Inhibitors

Antidepressive Agents, Tricyclic

Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for DESIPRAMINE HYDROCHLORIDE

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for DESIPRAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	204963-002	Dec 26, 2017	AB	RX	No	No
Ani Pharms	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	205153-001	Oct 28, 2016		DISCN	No	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-005	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Novast Labs	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	204963-005	Dec 26, 2017	AB	RX	No	No

Expired US Patents for DESIPRAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-006	Approved Prior to Jan 1, 1982
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-004	Approved Prior to Jan 1, 1982
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-001	Approved Prior to Jan 1, 1982
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-003	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory for Desipramine Hydrochloride

Last updated: February 19, 2026

What Is the Current Market Status of Desipramine Hydrochloride?

Desipramine hydrochloride is a tricyclic antidepressant (TCA) primarily indicated for depression. It also finds off-label use for neuropathic pain and other conditions. The global antidepressant market was valued at approximately USD 16.5 billion in 2022, with TCAs accounting for around 4%. Desipramine's specific share remains small due to limited manufacturing and declining demand for older antidepressants.

Major pharmaceutical companies have largely phased out the production of desipramine hydrochloride, favoring newer agents like SSRIs and SNRIs. Its generic availability is maintained but with declining regional prominence.

How Does the Patent and Regulatory Environment Influence Market Entry?

Desipramine hydrochloride has been off patent since the late 1980s. Regulatory approvals differ by jurisdiction, with the FDA classifying the drug as an approved, off-patent medication. Approvals for generic manufacturing restrict barriers for new entrants but lead to price competition rather than revenue growth.

Manufacturers face challenges in gaining approval for new formulations or delivery methods, limiting innovation. Existing medicines are classified as established molecules with low regulatory costs for generics, reducing barriers but also diminishing incentives for large-scale marketing investments.

What Are the Key Market Drivers and Barriers?

Drivers:

• Generic drug demand sustains growth in regions with limited access to newer antidepressants.
• Cost advantages of older, off-patent medications support use in low-income markets.
• Clinical needs for alternative treatments in specific patient populations.

Barriers:

• Competition from highly prescribed SSRIs and SNRIs, which have more favorable side effect profiles.
• Negative perception of TCAs due to anticholinergic adverse effects.
• Limited innovation and reformulation activity for desipramine hydrochloride.

What Is the Financial Trajectory for Desipramine Hydrochloride?

Revenue projections for desipramine hydrochloride are declining. Market data suggest global sales of generic TCAs diminished substantially over the past decade, with specific compounds like desipramine contributing marginally to the $16.5 billion antidepressant market in 2022.

For companies maintaining supply, revenues are estimated between USD 50 million and USD 150 million annually, predominantly from established markets such as India, China, and certain European countries. The decline is driven by reduced prescribing and competition.

Cost Analysis

Manufacturing costs for generics have decreased due to process improvements, with estimated production expenses below USD 0.50 per dosage unit. Pricing varies widely; in the United States, generic desipramine can be sold at USD 0.10 to USD 0.25 per pill.

Profitability Outlook

Profit margins are squeezed by intense price competition and declining demand. Some manufacturers report gross margins of 20-30%. Investment in R&D or marketing is minimal, given the medication’s status as an off-patent generic.

Future Revenue Outlook

Long-term revenue is expected to decline further due to:

• Market saturation.
• Increasing preference for newer antidepressants.
• Regulatory constraints on reformulations.

How Does Regional Variation Impact Market Dynamics?

In regions with limited access to newer therapies, demand for desipramine hydrochloride sustains at low to moderate levels. In countries like India and China, it remains a part of the essential medicines list, supporting ongoing sales. European and North American markets see negligible demand with a tendency toward prescription discontinuation.

What Are the Critical Factors for Stakeholders?

For Manufacturers:

• Maintaining low production costs.
• Navigating regulatory requirements.
• Exploring niche applications for off-label use.

For Investors:

• Recognizing declining revenue streams.
• Identifying opportunities in regional markets.
• Monitoring generics pipeline and regulatory shifts.

For Healthcare Providers:

• Weighing TCA side effects against newer therapies.
• Modifying prescribing patterns based on guidelines.

Key Takeaways

• Desipramine hydrochloride revenue is in decline, limited mainly to developing regions.
• Market share is eroded by newer antidepressants with better safety profiles.
• Price competition among generics restricts margins, with revenues estimated between USD 50 million and USD 150 million annually.
• Regulatory barriers are minimal, but innovation is limited.
• Future growth prospects are negligible due to persistent market saturation.

FAQs

1. Is there potential for new formulations of desipramine hydrochloride?

Limited. Regulatory hurdles and lack of perceived clinical benefit diminish incentives for reformulation.

2. What regions retain the highest demand?

India, China, and certain African markets. Demand remains low or declining in North America and Europe.

3. Are there any recent patent challenges or exclusivity issues?

No; the molecule has been off patent since the 1980s. Generics dominate the market.

4. What is the main competitive advantage for companies producing desipramine hydrochloride?

Cost-efficient manufacturing in emerging markets and potential niche off-label uses.

5. Could regulatory changes revive market interest?

Unlikely. The shift towards newer, safer antidepressants reduces the need for desipramine hydrochloride.

---

References

[1] Market Research Future. (2023). Global Antidepressants Market Analysis.
[2] IQVIA. (2022). Global Trends in Antidepressant Use.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
[4] PubChem. (2023). Desipramine Hydrochloride Data.
[5] World Health Organization. (2022). Essential Medicines List.